Voltage-gated potassium channel (KCNQ) is an essential regulator for cell membrane potential and neuronal excitability, and dysregulation has been associated with various neuronal disorders, including severe neonatal epileptic encephalopathy.A KCNQ2-5 activator, retigabine, was approved by EMA and FDA as an adjunctive therapy for focal onset seizures.However, this compound can dimerize in a redox environment and cause retinal pigment changes.The tissue distribution and mechanism of action of KCNQ family members have been examined, and central nervous-specific and M-Current mediate KCNQ2/3 channel selective activators have become the research and development direction of next-generation drugs.Xen-1101, CB03, and BHV7000 are currently in various stages of clin. research.A novel KCNQ2/3 selective activator, NS-041, has been identified and is currently undergoing IND enabling development.This compound can significantly lower channel open voltage and enhance the threshold of action potential.NS-041 also exhibited favorable ADME/PK properties and is an ideal candidate for QD po dose.Furthermore, this compound was evaluated in various seizure models, including MES, PTZ, and 6Hz mice models, and robust antiseizure efficacy was cross-confirmed.Safety evaluations were performed for both CNS side effects and repeat dosing general toxicity.Overall, NS-041 exhibited a good safety window and was accepted as a development candidate.More details will be presented.